Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
LY 3000328 (Cathepsin S inhibitor) 是 Cathepsin S 的选择性抑制剂,抑制人和小鼠Cat S 的IC50分别为7.7,1.67 nM。LY 3000328 (Cathepsin S inhibitor)可以通过抑制 Cathepsin S 介导的细胞外基质蛋白、弹性蛋白和胶原蛋白的降解来减缓或阻止腹主动脉瘤 (AAA) 扩张和 或降低 AAA 破裂的风险。